Medicilon Delivers One Stop Preclinical Support as Yizhong Pharma Secures NMPA Clinical Approval for YXC‑001 Tri‑functional Antibody Fusion Protein and YXC‑002 4th‑Generation EGFR Kinase Inhibitor
Yizhong Pharma, a STAR-Market-listed biotech company, has obtained Clinical Trial Approval Notices from the National Medical Products Administration (NMPA) for two proprietary innovative drug candidates: YXC-001, a tri functional antibody fusion protein, and YXC-002, a 4th-generation EGFR kinase inhibitor. As Yizhong Pharma’s CRO partner, Medicilon executed full-scope preclinical studies (PD, PK, Tox) for YXC -001 […]
4th SMC and AimedBio ADC Conference
Date: August 27-28, 2026
Venue:The Westin Seoul Parnas, South Korea – Medicilon Booth #6
ACS Fall 2026
Date: August 23-27, 2026
Venue: McCormick Place Convention Center, Chicago, IL – Medicilon Booth #400
【BRIDGE】Medicilon XDC Innovation Forum · Seoul 2026
Date: September 10, 2026 (Thursday)
Venue: EL Tower, Ruby Hall, Yangjae, Seoul
World’s First Phase III Positive B7-H3 ADC: Medicilon Congratulates MediLink Therapeutics on NDA Acceptance of Icontamrotamab
On July 18, China’s Center for Drug Evaluation (CDE) accepted the New Drug Application (NDA) for icontamrotamab for injection (Tam-Peli, YL201), a B7-H3-targeted ADC independently developed by MediLink Therapeutics. As the world’s first B7-H3 ADC with positive Phase III results, YL201 has officially entered its launch phase, offering a promising new treatment option for patients […]
Medicilon Webinar | IND-enabling Toxicity Studies, CTD Documentation and Translational Cardiac Risk Assessment
July 28th, 2026
6:00-7:00 PM (PST) | 9:00-10:00 PM (EST)
Medicilon Stands Out at ASMS 2026: Only CRO Selected for Bioanalysis Zone’s ‘Pick of the Posters’
The 74th ASMS Annual Conference on Mass Spectrometry and Allied Topics, held in San Diego from 31 May to 4 June 2026, drew thousands of leading experts from across the global mass spectrometry community. Among the ~3,000 posters presented, Bioanalysis Zone – a premier independent media platform in bioanalytical science – selected just fivefor its […]
Medicilon Congratulates Livzon Pharmaceutical on the Approval of LiYouBao® — China’s Only Export-Qualified r-FSH Injection Meeting Global International Standards
Livzon Pharmaceutical has secured NMPA marketing approval for LiYouBao®, its self-developed recombinant human follicle-stimulating hormone injection. The approval marks a key milestone for Livzon’s fertility pipeline, expanding its market-leading urinary FSH (u-FSH) product portfolio to build a dual u-FSH and recombinant FSH (r-FSH) technology platform. As Livzon’s trusted preclinical CRO partner, Medicilon provided integrated pharmacokinetic, […]
Medicilon Boston R&D Center Awarded Full AAALAC International Accreditation, Further Elevating Global Service Capabilities
Recently, Medicilon Boston R&D Center has successfully passed the rigorous review by AAALAC International and achieved full AAALAC International accreditation. Following the first AAALAC accreditation of its Shanghai R&D Center back in 2009, this renewed recognition proves that Medicilon’s Boston facility has met world-class standards in laboratory animal welfare, ethical supervision, quality management and operational […]
RACI Congress 2026
July 5-10, 2026
Perth Convention & Exhibition Centre, Perth, Western Australia
Medicilon Booth #9
